916136-76-0

Upstream product

• 540524-32-1 ethyl [2-({[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1H-indol-3-yl](oxo)acetate 
• 540524-34-3 3-(2-bromoethyl)-2-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1-(diphenylmethyl)-1H-indole 
• 540522-76-7 2-[2-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethanol 
• 540524-33-2 ethyl [1-benzhydryl-2-({[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1H-indol-3-yl](oxo)acetate 
• 540522-62-1 2-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1H-indole 
• 540522-61-0 2-(5-chloro-1H-indol-2-yl)ethanol 
• 540522-60-9 N-(2-bromo-4-chlorophenyl)-2,2,2-trifluoroacetamide 
• 873-38-1 4-chloro-2-bromoaniline 
• 540524-35-4 methyl 3-[4-({2-[2-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethyl}thio)phenyl]propanoate 

Downstream Products

• 540524-37-6 methyl 3-[4-({2-[5-chloro-1-(diphenylmethyl)-2-(2-hydroxyethyl)-1H-indol-3-yl]ethyl}sulfonyl)phenyl]propanoate 
• 540524-38-7 methyl 3-(4-{[2-(5-chloro-1-(diphenylmethyl)-2-{2-[(methylsulfonyl)oxy]ethyl}-1H-indol-3-yl)ethyl]sulfonyl}phenyl)propanoate 
• 540524-39-8 methyl 3-[4-({2-[2-(2-azidoethyl)-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethyl}sulfonyl)phenyl]propanoate 
• 540524-40-1 methyl 3-[4-({2-[2-(2-aminoethyl)-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethyl}sulfonyl)phenyl]propanoate 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION

The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}p

Indole cytosolic phospholipase A2 α inhibitors: Discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4- dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl} benzoic acid, efipladib

The optimization of a class of indole cPLA2α inhibitors is described herein. The importance of the substituent at C3 and the substitution pattern of the phenylmethane sulfonamide region are highlighted. Optimization of these regions led to the

Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis

This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.